Today LEO Pharma announced that the European Commission (EC) has granted marketing authorisation for Picato(R) (ingenol mebutate) gel as a treatment for actinic keratosis in the European Union (EU). Picato(R) gel is a once-daily, two or three day field-directed topical treatment for actinic keratosis, a common skin condition which if not treated can lead to squamous cell carcinoma, a form of non-melanoma skin cancer.[1] To view the Multimedia News Release, please click: http://multivu.prnewswire
LIV-24 applies ESG Tech AI technology, revolutionising industrial sector Cuts costs, increases productivity, facilitates sustainable business
—
At present,...
TAT and International Partners Urge Thai Businesses to Prepare for Imminent EU Regulations on Sustainable Tourism
—
On September 26, at the Avani+ Riversi...
International efforts to protect and empower ASEAN's women migrant workers
—
International organisations under the United Nations (UN) and the European Un...
EXPORT PROMOTION SEMINAR TO HIGHLIGHT EXCELLENCE OF EUROPEAN FOOD
—
H.E. Mr. David Daly, Ambassador of the European Union to Thai (EU) is set to host a tw...
Vaxzevria approved in the EU as third dose booster against COVID-19
—
Approval follows CHMP recommendation for use in patients previously vaccinated with ...
'EU Sustainable Food & Craft Market' champions sustainable SMEs to mark Europe Day
—
To celebrate Europe Day 2022, the Delegation of the European Unio...
TH-EU: The Phuket Youth's Awareness Raising for Separate Collection
—
Today, the Prince of Songkhla University, Phuket Campus was the hub to learn and exc...
BLUE ELEPHANT GROUP'S STEPPE FAMILY MEETS AMBASSADOR OF THAILAND TO BELGIUM
—
H.E. Mr. Sek Wannamethee (2nd from left), Head of the Thai delegation to the...